看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Revenue Multiple | 2.0x - 2.2x | 2.1x |
| Selected Fwd Revenue Multiple | 5.0x - 5.5x | 5.2x |
| Fair Value | $18.47 - $20.51 | $19.49 |
| Upside | 8.6% - 20.6% | 14.6% |
| Benchmarks | Ticker | Full Ticker |
|---|---|---|
| PTC Therapeutics, Inc. | BH3 | DB:BH3 |
| AC Immune SA | IMR | DB:IMR |
| Kuros Biosciences AG | KURN | SWX:KURN |
| Molecular Partners AG | MOLN | SWX:MOLN |
| Basilea Pharmaceutica AG | BSLN | SWX:BSLN |
| Santhera Pharmaceuticals Holding AG | SPHD.F | OTCPK:SPHD.F |
| Select LTM Revenue Multiple | ||||||||
| Benchmark Companies | ||||||||
| BH3 | IMR | KURN | MOLN | BSLN | SPHD.F | |||
| DB:BH3 | DB:IMR | SWX:KURN | SWX:MOLN | SWX:BSLN | OTCPK:SPHD.F | |||
| Historical Revenue Growth | ||||||||
| 5Y CAGR | 21.3% | -24.4% | 96.8% | -24.6% | 9.2% | 26.7% | ||
| 3Y CAGR | 14.4% | NM- | 76.2% | -20.1% | 12.1% | 90.3% | ||
| Latest Twelve Months | -14.0% | 84.5% | 125.1% | -29.4% | 32.3% | 2100.5% | ||
| Historical EBIT Profit Margin | ||||||||
| 5 Year Average Margin | -59.7% | -405956.1% | -117.2% | -569.5% | 4.2% | -1563.1% | ||
| Prior Fiscal Year | -37.3% | -362.3% | -15.2% | -868.3% | 13.9% | -612.4% | ||
| Latest Fiscal Year | -18.2% | -191.8% | 0.1% | -1231.7% | 29.6% | 49.5% | ||
| Latest Twelve Months | -18.2% | -191.8% | 0.1% | -1231.7% | 29.6% | 47.3% | ||
| Current Trading Multiples | ||||||||
| EV / LTM Revenue | 5.83x | -0.67x | 8.53x | -5.54x | 2.25x | 1.51x | ||
| EV / LTM EBIT | -32.1x | 0.3x | 6024.9x | 0.4x | 7.6x | 3.2x | ||
| Price / LTM Sales | 4.20x | 4.61x | 8.75x | 24.04x | 2.29x | 1.42x | ||
| Low | Mid | High | ||||||
| Benchmark EV / LTM Revenue | -5.54x | 2.25x | 8.53x | |||||
| Historical EV / LTM Revenue | 2.40x | 3.23x | 27.05x | |||||
| Selected EV / LTM Revenue | 1.97x | 2.08x | 2.18x | |||||
| (x) LTM Revenue | 114 | 114 | 114 | |||||
| (=) Implied Enterprise Value | 224 | 236 | 248 | |||||
| (-) Non-shareholder Claims * | (10) | (10) | (10) | |||||
| (=) Equity Value | 215 | 227 | 238 | |||||
| (/) Shares Outstanding | 12.6 | 12.6 | 12.6 | |||||
| Implied Value Range | 17.05 | 17.99 | 18.93 | |||||
| FX Rate: CHF/USD | 0.8 | 0.8 | 0.8 | Market Price | ||||
| Implied Value Range (Trading Cur) | 20.90 | 22.05 | 23.20 | 17.01 | ||||
| Upside / (Downside) | 22.9% | 29.7% | 36.4% | |||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | BH3 | IMR | KURN | MOLN | BSLN | SPHD.F | |
| Enterprise Value | 4,538 | (46) | 645 | (28) | 469 | 184 | |
| (+) Cash & Short Term Investments | 1,153 | 165 | 18 | 149 | 121 | 16 | |
| (+) Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Debt | (2,471) | (5) | (2) | (2) | (112) | (26) | |
| (-) Other Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 3,220 | 114 | 661 | 119 | 479 | 175 | |
| (/) Shares Outstanding | 78.9 | 98.9 | 38.0 | 36.9 | 12.1 | 12.6 | |
| Implied Stock Price | 40.83 | 1.16 | 17.41 | 3.24 | 39.45 | 13.88 | |
| FX Conversion Rate to Trading Currency | 1.13 | 0.93 | 1.00 | 1.00 | 1.00 | 0.82 | |
| Implied Stock Price (Trading Cur) | 36.00 | 1.25 | 17.41 | 3.24 | 39.45 | 17.01 | |
| Trading Currency | EUR | EUR | CHF | CHF | CHF | USD | |
| FX Rate to Reporting Currency | 1.13 | 0.93 | 1.00 | 1.00 | 1.00 | 0.82 | |